Phuturdex › Diseases › Multiple myeloma
Drugs in development · updated 30 October 2026
Multiple myeloma: drugs in development
As of 30 October 2026 there are 531 active clinical trials (recruiting or ongoing, phases I–III) on 272 drugs for multiple myeloma. 137 are experimental, that is not yet approved in the United States.
Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.
Sign in free →Experimental drugs
Not yet approved by the US FDA for any indication.
Sorted by most advanced phase and number of active trials. Showing 40 of 137 drugs.
Approved drugs in new trials
Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| DexamethasoneDexametasone, Dextenza | II–III | 209 | NCT07887984 |
| LenalidomideRevlimid, lenalinomide | II–III | 127 | NCT07887984 |
| DaratumumabDarzalex | II–III | 120 | NCT07887984 |
| BortezomibVelcade, Bortezomib Hospira® | II–III | 86 | NCT07887984 |
| PomalidomideImnovid, Pomalyst® | II–III | 78 | NCT06879379 |
| CarfilzomibKitprozy®, Kyprolis® | II–III | 63 | NCT04513639 |
| CyclophosphamideCyclophosphamid, Cytoxan | III | 50 | NCT07903506 |
| IsatuximabIsatuximab SAR650984, Sarclisa Escena® | II–III | 43 | NCT07732712 |
| TeclistamabTecvayli® | II–III | 39 | NCT07887984 |
| Belantamab mafodotinGSK2857916, Blenrep® | III | 38 | NCT07285239 |
| ElranatamabElrantamab, Elrexfio® | III | 31 | NCT05623020 |
| FludarabineFludara, FLUDARABIN | III | 29 | NCT07903506 |
| IberdomideCC-220, Zenbexus® | III | 28 | NCT07624513 |
| TalquetamabTalvey® | II–III | 28 | NCT07887984 |
| SelinexorKPT-330, Xpovio® | III | 22 | NCT07623798 |
Sorted by most advanced phase and number of active trials. Showing 15 of 135 drugs.
All 272 drugs, with the details
In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.
Open in Phuturdex →Specific forms
- Plasma cell leukemia 22 drugs
- Acute myeloid leukemia 314 drugs
- Precursor lymphoblastic lymphoma/leukemia 163 drugs
- Acute biphenotypic leukaemia 80 drugs
- Prolymphocytic leukemia 15 drugs
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive 68 drugs
- Myelodysplastic Syndromes 203 drugs
- Myeloid leukemia 26 drugs
- Burkitt lymphoma 113 drugs
- T-cell lymphoma 74 drugs
- Chronic lymphocytic leukemia 137 drugs
- Lymphoma, B-Cell, Marginal Zone 86 drugs
Broader categories
- Cardiovascular disease 71 drugs
- Hemorrhagic disease 6 drugs
- Vascular disease 16 drugs
- Immune System Diseases 54 drugs
- Immunoproliferative disorder 16 drugs
- Hemostatic Disorders 6 drugs
Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D009101 “Multiple Myeloma”. Prevalence: Orphanet.